BOSTON—PepGen Inc. (Nasdaq: PEPG), a biotechnology company developing next-generation oligonucleotide therapies for severe neuromuscular and neurological diseases, has announced the appointment of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors.
The two industry veterans bring decades of experience in life sciences, bolstering PepGen’s leadership team as it advances its mid-stage clinical trials and expands its Enhanced Delivery Oligonucleotide (EDO) platform.
“We are thrilled to welcome Lisa and Mitch to our Board of Directors,” said James McArthur, PhD, President and CEO of PepGen. “Lisa’s expertise in scaling manufacturing and navigating global regulatory agencies, alongside Mitch’s deep experience in scientific innovation and therapy development, will provide critical guidance as we work to bring transformative treatments to patients.”
Bringing Expertise in Manufacturing, Regulatory, and Innovation
Lisa Wyman, currently Chief Technical and Quality Officer at Scholar Rock, has extensive experience leading technical operations and quality control in the biopharmaceutical industry. Previously, she served as Chief Technical Operations Officer and Chief Digital Officer at Generate:Biomedicines and was instrumental in Acceleron Pharma’s growth, playing a key role in its $11.5 billion acquisition by Merck & Co. She also helped develop and launch treatments such as Winrevair™ and Reblozyl®.
Dr. Mitchell Finer, a seasoned leader in gene therapy and regenerative medicine, is a co-founder and Strategic Advisor for ElevateBio. He previously served as Chief Scientific Officer at bluebird bio, overseeing the development of four FDA-approved genetic therapies, including Abecma® for multiple myeloma and Zynteglo® for beta thalassemia. With over 34 years of experience, he has played a pivotal role in numerous biotech ventures, holding leadership positions at companies such as Adverum Biotechnologies, Oncorus, and TCR Therapeutics.
With these new appointments, PepGen is reinforcing its commitment to advancing breakthrough treatments for patients with severe neuromuscular conditions.
